Protara Therapeutics (TARA) Price & Analysis

Compare

1,240 Followers

TARA Stock Chart & Stats

$6.74

-$0.26(-4.26%)

At close: Jan 08 4:00 PM EST

$6.74

-$0.26(-4.26%)

Day’s Range― - ―

52-Week Range$2.51 - $10.48

Previous CloseN/A

Volume145.20K

Average Volume (3M)539.58K

Market Cap

$260.08M

Enterprise Value$54.87M

Total Cash (Recent Filing)$132.67M

Total Debt (Recent Filing)$3.66M

Price to Earnings (P/E)―

Beta0.91

Next Earnings

Mar 11, 2026

EPS Estimate

-0.35

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.31

Shares Outstanding38,587,260

10 Day Avg. Volume856,586

30 Day Avg. Volume539,581

Financial Highlights & Ratios

PEG Ratio0.06

Price to Book (P/B)0.65

Price to Sales (P/S)0.00

P/FCF Ratio-3.03

Enterprise Value/Market Cap0.21

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-623.52

Enterprise Value/Ebitda-0.97

Forecast

1Y Price Target

$25.00

Price Target Upside270.92% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

EPS Forecast (FY)-1.41

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Trial SuccessProtara reported positive interim data from the Phase 2 STARBORN-1 trial with TARA-002 in macrocystic and mixed lymphatic malformations, with 83% of patients achieving a complete response.

Market OpportunityOngoing BCG shortages leave physicians with limited treatment options for HR patients, which presents an opportunity that TARA-002 is well positioned to fill based on its simple administration, safety profile, and promising early efficacy data.

Regulatory DevelopmentsThe FDA is expected to provide regulatory clarity for TARA-002, which could enhance its market potential.

Bears Say

Financial ConstraintsThe company has approximately 1.6 years of cash left, indicating potential financial constraints in the near future.

Investor SentimentThe company faces a short interest of 8% of its float, which could indicate skepticism among investors.

Regulatory ChallengesThere is uncertainty about how the FDA will react to the interim update from the STARBORN-1 trial.

Protara Therapeutics News

Protara announces updated interim data from Phase 2 ADVANCED-2 trial

Protara Therapeutics (TARA) announced updated interim data from the ongoing Phase 2 open-label ADVANCED-2 trial of TARA-002 in...

24h ago

TARA

Protara announces results from Phase 2 STARBORN-1 trial of TARA-002

Protara Therapeutics (TARA) announced positive interim results from its ongoing Phase 2 open-label STARBORN-1 trial assessing intracystic injection...

15d ago

TARA

Protara Therapeutics reports Q3 EPS (31c), consensus (38c)

“We have made important advancements across our clinical programs this year, and with many significant milestones in the...

24d ago

TARA

Protara Therapeutics sees cash runway into mid-2027

As of September 30, 2025, unrestricted cash and cash equivalents and investments in marketable debt securities totaled $133.6...

24d ago

TARA

Protara’s TARA-002: Promising Efficacy and Clear Regulatory Path Justify Buy Rating

Analyst Andres Y. Maldonado of H.C. Wainwright reiterated a Buy rating on Protara Therapeutics, retaining the price target...

20h ago

TARA

Buy Rating for Protara Therapeutics Driven by Promising Bladder Cancer Drug Trial

JonesTrading analyst Soumit Roy has maintained their bullish stance on TARA stock, giving a Buy rating today. Soumit...

20h ago

TARA

Buy Recommendation for Protara Therapeutics Driven by Promising TARA-002 Developments and Strategic Market Positioning

Analyst Charles Zhu of LifeSci Capital maintained a Buy rating on Protara Therapeutics, retaining the price target of...

20h ago

TARA

Protara Therapeutics Announces Promising Phase 2 Trial Results

Protara Therapeutics ( ($TARA) ) has shared an update. On December 3, 2025, Protara Therapeutics announced updated interim...

23h ago

TARA

Protara Therapeutics’ TARA-002: A Promising Alternative for NMIBC Amidst BCG Shortages

In a report released today, Andres Y. Maldonado from H.C. Wainwright reiterated a Buy rating on Protara Therapeutics,...

10d ago

TARA

Protara Therapeutics’ TARA-002: Promising Phase 2 Results Bolster Buy Rating Amidst FDA Uncertainty

JonesTrading analyst Soumit Roy has maintained their bullish stance on TARA stock, giving a Buy rating today. Soumit...

15d ago

TARA

Promising Phase 2 Results and Strategic Planning Justify Buy Rating for TARA-002

H.C. Wainwright analyst Andres Y. Maldonado reiterated a Buy rating on Protara Therapeutics today and set a price...

15d ago

TARA

Protara Therapeutics Announces Promising Phase 2 Trial Results

Protara Therapeutics ( ($TARA) ) has issued an update. On November 19, 2025, Protara Therapeutics announced interim results...

15d ago

TARA

Protara Therapeutics: Promising Developments and Strategic Positioning Drive Buy Rating

LifeSci Capital analyst Charles Zhu has maintained their bullish stance on TARA stock, giving a Buy rating on...

17d ago

TARA

Protara Therapeutics Reports Q3 2025 Financial Results

Protara Therapeutics, Inc. ( ($TARA) ) has released its Q3 earnings. Here is a breakdown of the information...

22d ago

TARA

TARA FAQ

What was Protara Therapeutics’s price range in the past 12 months?

Protara Therapeutics lowest stock price was $2.51 and its highest was $10.48 in the past 12 months.

What is Protara Therapeutics’s market cap?

Protara Therapeutics’s market cap is $260.08M.

When is Protara Therapeutics’s upcoming earnings report date?

Protara Therapeutics’s upcoming earnings report date is Mar 11, 2026 which is in 97 days.

How were Protara Therapeutics’s earnings last quarter?

Protara Therapeutics released its earnings results on Nov 10, 2025. The company reported -$0.31 earnings per share for the quarter, beating the consensus estimate of -$0.384 by $0.074.

Is Protara Therapeutics overvalued?

According to Wall Street analysts Protara Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Protara Therapeutics pay dividends?

Protara Therapeutics does not currently pay dividends.

What is Protara Therapeutics’s EPS estimate?

Protara Therapeutics’s EPS estimate is -0.35.

How many shares outstanding does Protara Therapeutics have?

Protara Therapeutics has 38,587,260 shares outstanding.

What happened to Protara Therapeutics’s price movement after its last earnings report?

Protara Therapeutics reported an EPS of -$0.31 in its last earnings report, beating expectations of -$0.384. Following the earnings report the stock price went up 5.594%.

Which hedge fund is a major shareholder of Protara Therapeutics?

Currently, no hedge funds are holding shares in TARA

Protara Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-49.42%

Trailing 12-Months

Asset Growth

53.72%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Protara Therapeutics

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.

Protara Therapeutics (TARA) Earnings & Revenues

Historic Earnings Reports

TARA Stock 12 Month Forecast

Average Price Target

$25.00

▲(270.92% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","16":"$16","31":"$31","8.5":"$8.5","23.5":"$23.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$30.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$25.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$21.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,8.5,16,23.5,31],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.18,7.089230769230769,8.998461538461537,10.907692307692308,12.816923076923077,14.726153846153846,16.635384615384616,18.544615384615383,20.453846153846154,22.363076923076925,24.27230769230769,26.181538461538462,28.090769230769233,{"y":30,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.18,6.704615384615384,8.22923076923077,9.753846153846155,11.278461538461539,12.803076923076922,14.327692307692308,15.852307692307694,17.376923076923077,18.90153846153846,20.426153846153845,21.950769230769232,23.475384615384616,{"y":25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.18,6.396923076923077,7.613846153846154,8.830769230769231,10.047692307692309,11.264615384615386,12.481538461538461,13.698461538461538,14.915384615384616,16.13230769230769,17.349230769230772,18.566153846153846,19.783076923076923,{"y":21,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.47,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.53,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.28,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.92,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.74,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.01,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.46,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.3,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.06,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.17,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.41,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.18,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >